Nuwellis Reports 31 Aquadex Console Sales in First Half of 2026
Nuwellis (NASDAQ:NUWE) has sold 31 Aquadex SmartFlow consoles year-to-date as of September 2026, surpassing the full-year sales recorded in seven of the previous ten years. This growth is contributing to a broader trend of U.S. revenue increasing by 26% compared to the first half of 2025 across three clinical markets: pediatrics, critical care, and heart failure. The company's business model relies on recurring revenue from disposable blood circuits used with each installed console. While increased console sales create potential for higher consumable purchases, actual financial impact depends heavily on hospital utilization rates. Nuwellis has not yet provided updated full-year guidance or detailed metrics such as total installed consoles or average usage. Investors are watching whether the current pace of adoption will lead to one of the company's top three annual console sales figures and if this growth translates into sustained increases in consumable revenue.
Tickers: $NUWE
Topics: console sales medical technology recurring revenue U.S. market growth